What’s the current market cap for Vericel stock?

Vericel (VCEL) has a market cap of $1.8B as of May 25, 2026.

What is the P/E ratio for Vericel stock?

The price to earnings (P/E) ratio for Vericel (VCEL) stock is 82.39 as of May 25, 2026.

Does Vericel stock pay dividends?

No, Vericel (VCEL) stock does not pay dividends to its shareholders as of May 25, 2026.

When is the next Vericel dividend payment date?

Vericel (VCEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Vericel?

Vericel (VCEL) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Vericel stock | $VCEL Share Price

13:30

15:10

16:45

18:25

20:00

About Vericel

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Ticker

$VCEL

Sector

Health

Primary listing

NASDAQ

Employees

398

Headquarters

Cambridge, United States

Website

www.vcel.com

Vericel Metrics

BasicAdvanced

$1.8bn

82.39

$0.42

1.16

What the Analysts think about Vericel

Analyst ratings (Buy, Hold, Sell) for Vericel stock.

Bulls say / Bears say

Vericel’s Q1 2026 net revenue climbed 30% year-over-year to $68.4 million, beating consensus by over 7% powered by MACI (up 22%) and Burn Care (up 91%), with gross margin increasing to 72%.

Management raised full-year 2026 revenue guidance by $10 million to $326–$336 million, signifying confidence in ongoing MACI growth and anticipated BARDA-backed NexoBrid procurement of $5–$6 million in the second half.

Vericel finished Q1 with around $211 million in cash and investments, zero debt, and generated $15.1 million in free cash flow, offering plenty of liquidity to support its Burlington plant and pipeline projects.

Operating expenses rose in Q1 due to an expanded MACI sales force and the commissioning of the new Burlington facility, resulting in a net loss of $6.3 million despite revenue growth.

Revenue is still highly concentrated in MACI, which made up over 82% of Q1 sales ($56.4 million out of $68.4 million), highlighting limited diversification and exposure to trends in the orthopedic cartilage market.

Vericel must pay MediWound up to $125 million in contingent sales milestone payments under the NexoBrid license, which could put pressure on future cash flow if milestones are met.

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

Vericel Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Vericel Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VCEL

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Vericel’s Q1 2026 net revenue climbed 30% year-over-year to $68.4 million, beating consensus by over 7% powered by MACI (up 22%) and Burn Care (up 91%), with gross margin increasing to 72%.

Operating expenses rose in Q1 due to an expanded MACI sales force and the commissioning of the new Burlington facility, resulting in a net loss of $6.3 million despite revenue growth.

Vericel must pay MediWound up to $125 million in contingent sales milestone payments under the NexoBrid license, which could put pressure on future cash flow if milestones are met.

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.